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Evidence from in vivo, in vitro and ecological studies are suggestive of a protective effect of vitamin D against pancreatic cancer (PC).
However, this has not been confirmed by analytical epidemiological studies. We aimed to examine the association between pre-
diagnostic circulating vitamin D concentrations and PC incidence in European populations. We conducted a pooled nested case-control
study within the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Nord-Trøndelag Health Study’s second
survey (HUNT2) cohorts. In total, 738 primary incident PC cases (EPIC n5626; HUNT2 n5112; median follow-up56.9 years) were
matched to 738 controls. Vitamin D [25(OH)D2 and 25(OH)D3 combined] concentrations were determined using isotope-dilution liquid
chromatography-tandem mass spectrometry. Conditional logistic regression models with adjustments for body mass index and smok-
ing habits were used to estimate incidence rate ratios (IRRs) and 95% confidence intervals (95%CI). Compared with a reference cate-
gory of >50 to 75 nmol/L vitamin D, the IRRs (95% CIs) were 0.71 (0.42–1.20); 0.94 (0.72–1.22); 1.12 (0.82–1.53) and 1.26 (0.79–
2.01) for clinically pre-defined categories of 25; >25 to 50; >75 to 100; and >100 nmol/L vitamin D, respectively (p for trend50.09).
Corresponding analyses by quintiles of season-standardized vitamin D concentrations also did not reveal associations with PC risk (p
for trend50.23). Although these findings among participants from the largest combination of European cohort studies to date show
increasing effect estimates of PC risk with increasing pre-diagnostic concentrations of vitamin D, they are not statistically significant.
Pancreatic cancer (PC) is a relatively rare form of cancer in
Europe, with annual incidence rates of 8.3/100,000 in men
and 5.5/100,000 in women.1 However, it is an aggressive and
devastating malignancy, which is characterised by invasive-
ness, rapid progression and resistance to treatment. As a
result, 5-year survival rates in Europe are only 7%.2 Preven-
tion is, therefore, key, but with the exception of family
history, chronic pancreatitis, diabetes mellitus, smoking, alco-
hol and obesity as established risk factors,3,4 a large part of
the etiology of PC remains unknown. The identification of
(other) modifiable risk factors is, therefore, warranted.
A potentially interesting factor in this respect is vitamin
D. In general, vitamin D and its derivatives have been shown
to have significant anti-carcinogenic properties.5,6 The
What’s new?
Living at lower latitude and increased ultraviolet light exposure are inversely correlated with pancreatic cancer (PC) risk, sup-
porting a model where vitamin D may protect from this devastating cancer. Here, the authors performed the largest combination of
European studies to date and find that higher vitamin D concentrations are not associated with a lower risk of PC. They recommend
caution before guidelines to increase vitamin D concentrations for the prevention of cancer can be recommended.
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expression of the enzyme 25-hydroxyvitamin D-1 a-
hydroxylase that catalyses the established biomarker of vita-
min D status, 25(OH)D,7 to the active vitamin D form,
1a,25(OH)2 D, has been observed in pancreatic duct cells,
and in normal and adenocarcinomatous tissues.8,9 Further-
more, vitamin D analogs inhibit PC cell proliferation, induce
differentiation, promote apoptosis and repress metastasis in
vitro10–18 and inhibit pancreatic tumour growth in
vivo.12,13,16,18
Ecological studies have shown that lower latitude and
increased ultraviolet B (UVB) radiation are inversely related
to PC risk and mortality19–21 and a preventive role of vitamin
D has been suggested. However, an ecological study design
has several weaknesses and the validity of associations might
be questioned. Analytical epidemiologic studies on vitamin D
in relation to PC risk have been conducted, with conflicting
results.
In prospective nested case–control studies, blood concen-
trations of vitamin D have been investigated, which better
reflects total vitamin D status. In the Alpha-Tocopherol,
Beta-Carotene (ATBC) Cancer Prevention Study of male
smokers from Finland,22 higher vitamin D concentrations
were associated with an increased risk of PC, whereas no
overall association was observed in a first report, but an
increased risk was shown in a second report of the Prostate,
Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
from the United States (US).23,24 When the ATBC and PLCO
studies were combined with four other studies from the US
and two from China in the Cohort Consortium Vitamin D
Pooling Project of Rarer Cancers (VDPP), including 952 PC
cases and 1333 controls, an increased risk with higher vita-
min D concentrations was observed.25 However, a pooled
analysis of 451 PC cases and 1167 controls from five US
studies, different from those in the VDPP, showed an inverse
association.26
Except for the single study from Finland,22 which was
based on male smokers only, no studies on vitamin D con-
centrations in relation to PC risk have been performed in
European populations. Given the paucity of information
from European populations, particularly from prospective
cohort studies where biological samples are collected before
cancer onset, we conducted a pooled nested case–control
study within the European Prospective Investigation into
Cancer and Nutrition (EPIC) and the Nord-Trøndelag Health
Study’s second survey (HUNT2) cohorts to examine the asso-
ciation between pre-diagnostic circulating concentrations of
vitamin D and the incidence of PC.
Material and Methods
Study population
Both the EPIC and HUNT2 cohorts have previously been
described in detail.27,28 In brief, EPIC is a multicentre pro-
spective cohort study designed to investigate the association
between diet, various lifestyle and environmental factors and
the incidence of different forms of cancer and other chronic
diseases. It consists of cohorts in 23 centres from 10 Euro-
pean countries: Denmark, France, Germany, Greece, Italy,
The Netherlands, Norway, Spain, Sweden and the United
Kingdom. A total of 521,448 subjects joined the study
between 1992 and 2000. Habitual dietary intake for the past
12 months was assessed using validated country-specific food
frequency questionnaires29,30 and country-specific food com-
position tables. Participants also completed a lifestyle ques-
tionnaire, had their anthropometric measurements recorded
(self-reported in France, Norway and Oxford) and donated a
blood sample (in approximately 80% of cohort participants).
These blood samples were processed, aliquoted and stored in
heat-sealed straws at 21968C under liquid nitrogen at the
International Agency for Research on Cancer (IARC) for all
countries except Denmark and Sweden, where tubes were
stored at 21508C under nitrogen vapour or at 2808C in
freezers, respectively.
Incident PC cases were identified through record linkage
with regional cancer registries in Denmark, Norway, The
Netherlands, Spain, Sweden, the United Kingdom and in
most of the Italian centres. In France, Germany, Greece and
Naples (Italy), follow-up was based on a combination of
methods, including health insurance records, cancer and
pathology registries and active follow-up through study par-
ticipants and their next-of-kin. Closure dates for our study
were defined as the latest date of complete follow-up and
ranged from December 2007 to December 2008 for centres
using registry data and from June 2005 to December 2009
for centres using active follow-up procedures.
All participants gave written informed consent, and the
study was approved by the Ethics Review Committee of
IARC and by the local ethical committee of individual EPIC
centres.
The HUNT study was initiated in 1984, inviting the total
adult population of over 20 years of age in the county of
Nord-Trøndelag in Norway for a general population-based
health screening. The main emphasis was initially on hyper-
tension and diabetes, but this was later extended to include a
large number of health problems and disease categories. For
our analyses, the 65,237 participants of the second HUNT
survey (HUNT2) were included. Between 1995 and 1997,
these participants filled out questionnaires on a wide range of
topics (e.g., use of alcohol and tobacco, physical activity and
medical history), had a clinical examination and donated a
blood sample. These samples were stored in a biobank at
2808C.
Based on the unique national identity number, assigned to
all Norwegian residents, the participants in HUNT are linked
to different national registries to access migration, emigra-
tion, cancer incidence and mortality data. The last record
linkages for our study with the Norwegian Cancer Registry
identified cancer cases diagnosed until September 2007.
All participants gave written informed consent at baseline,
including future linkage to national registries, and the study
was recommended by the Regional Committee for Medical
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Research Ethics and approved by the Data Inspectorate of
Norway.
Nested case–control design
Cases in our study included primary incident pancreatic
adenocarcinomas (International Classification of Diseases for
Oncology, Third Edition, codes C250–C259 or C25.0–C25.3
and C25.7–C25.9). Endocrine pancreatic tumours (code
C25.4; histology types 8150, 8151, 8153, 8155, 8240 and
8246) were excluded, because the aetiology of these cancers
may be different.
During the follow-up period, 1,013 PC cases were identi-
fied in the EPIC cohort. Of these, 33 endocrine cases were
excluded. After further exclusions (283 cases who did not
have blood sample available, two cases who had in situ
tumours or tumours of non-malignant morphology, 65 cases
who had a secondary tumour and four cases who did not
have lifestyle data available), a total of 626 incident PC cases
with available questionnaire data and blood samples were
identified for our study.
In the HUNT2 cohort, 117 PC cases were identified, of
which 5 endocrine tumours were excluded, leaving 112 inci-
dent cases for our study.
Among this total of 738 cases, 493 (67%) were microscop-
ically confirmed, based on histology of the primary tumour
(N5 251), histology of the metastasis (N5 82), cytology
(N5 117) or autopsy (N5 43).
Control subjects were selected by incidence density sam-
pling from all cohort members alive and free of cancer
(except non-melanoma skin cancer) at the time of diagnosis
of the matching case and were matched to cases by study
centre, sex, duration of follow-up, age at blood collection (6
1 month to6 5 years) and fasting status at the time of blood
collection (< 3 hrs (not fasting), 3–6 hrs (in between) or> 6
hrs (fasting)). For the EPIC study, participants were also
matched on date of blood collection (6 1 month to6 1 year)
and time of blood collection (6 1 hrs to6 4 hrs). For every
case, one matched control was identified.
Laboratory measurements
Concentrations of both forms of vitamin D status [25(OH)D2
and 25(OH)D3] were measured in blood serum (plasma for
the samples of Umea [Sweden]), using isotope-dilution liquid
chromatography (LC) tandem-mass spectrometry (MS/MS),31
at the department of clinical chemistry, Canisius Wilhelmina
Hospital in Nijmegen, The Netherlands. The inter-assay coef-
ficients of variation were 5.3%, 3.1% and 2.9% at 25(OH)D3
concentrations of 39.0, 92.5 and 127.0, nmol/L, respectively,
and 9.5%, 5.5% and 5.6% at 25(OH)D2 concentrations of
32.9, 57.3 and 111.0 nmol/L, respectively. For technical rea-
sons, EPIC and HUNT2 samples were measured sequentially.
In addition, 11% of case–control sets were not measured in
the same analytical batch. However, batch to batch differ-
ences are considered to be minor: no significant between-day
drift, time shifts or other trends were observed. For all
analyses, laboratory technicians were blinded to case–control
status of the samples.
Concentrations of 25(OH)D2 were only observed in 24
persons (1.6%) of the population, of which 3 came from
Denmark, 4 from Spain, 13 from Sweden and 4 from the
HUNT2 cohort in Norway. For our analyses, total vitamin D
status was evaluated by adding 25(OH)D2 to 25(OH)D3
concentrations.
Data analysis
Means with standard deviations, medians with interquartile
ranges or frequencies (where appropriate) of baseline charac-
teristics were computed and compared between cases and
controls of the EPIC and HUNT2 cohorts separately. Differ-
ences between cases and controls were tested by paired t test
or by conditional logistic regression.
An incidence rate ratio (IRR), which is the interpretation
of an odds ratio in an incidence density sampling design,32
and 95% confidence interval (95% CI) for the association
between vitamin D status and PC was estimated by condi-
tional logistic regression analysis.
To compare our findings with results from literature, vita-
min D concentrations were divided into five categories (25;
>25 to 50; >50 to 75; >75 to 100 and >100 nmol/L)
according to clinically defined cut-points, which are based on
the proposed levels of vitamin D deficiency, insufficiency and
sufficiency.33–36 The middle category was used as reference to
provide stability in the statistical analyses. To test for trend
across categories, the categories of vitamin D were modelled
as continuous variables, in which each category was assigned
the median value of controls in that category.
In addition, vitamin D concentrations were divided into
overall quintiles as well as cohort-specific quintiles, defined
by the distribution in control subjects. Vitamin D concentra-
tions were also log2-transformed. The IRR for a log2-trans-
formed variable corresponds to the change in PC risk by
doubling the blood concentrations.
Since season of blood collection may affect vitamin D lev-
els, two approaches were used to take this into account: (i)
adjustment for month of blood collection; (ii) standardization
of vitamin D levels by adding the overall mean of vitamin D
for all subjects to the residuals derived from (iia) a simple
regression model fitted to vitamin D concentration by month
of blood collection, (iib) a regression of vitamin D levels on
the periodic function – sin(2pX/12) – cos (2pX/12), where X
is the month of blood collection; and (iic) a non-parametric
local regression (PROC LOESS; SAS Institute, Cary, NC)
with vitamin D status as the dependent variable and week of
the year of blood donation as the independent variable.37,38
Since the results were similar for all different approaches to
take seasonal variation into account, adjustment by LOESS
residuals was used in all final models on quintiles and a dou-
bling of vitamin D concentrations.
IRR estimates were computed both in a crude model,
which was conditioned on the matching factors and in a
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Table 1. Description of PC cases and matched controls for the EPIC and HUNT2 studies separately
EPIC HUNT2
Cases
(n5626)
Matched controls
(n5626) p value1
Cases
(n5112)
Matched controls
(n5112) p value1
Matched variables
Years of follow-up, mean (sd) 7.0 (3.7) – – 5.8 (3.2) – –
Age at recruitment (years), mean (sd) 57.7 (7.8) 57.7 (7.8) – 68.0 (10.7) 68.0 (10.6) –
Women, n (%) 337 (53.9) 337 (53.9) – 59 (52.7) 59 (52.7) –
Residential region, n (%) – –
North (UK, NL, Germany, Denmark,
Sweden, Norway)
457 (73.0) 457 (73.0) 112 (100.0) 112 (100.0)
South (France, Italy, Spain, Greece) 169 (27.0) 169 (27.0) – –
Country, n (%)
HUNT2 cohort –
Norway – – 112 (100.0) 112 (100.0)
EPIC cohort –
Denmark 79 (12.6) 79 (12.6) – –
France 12 (1.9) 12 (1.9) – –
Germany 86 (13.7) 86 (13.7) – –
Greece 36 (5.8) 36 (5.8) – –
Italy 66 (10.5) 66 (10.5) – –
The Netherlands 62 (9.9) 62 (9.9) – –
Norway 5 (0.8) 5 (0.8) – –
Spain 55 (8.8) 55 (8.8) – –
Sweden 145 (23.2) 145 (23.2) – –
United Kingdom 80 (12.8) 80 (12.8) – –
Season of blood collection, n (%) – –
Winter (Dec, Jan, Feb) 134 (21.4) 135 (21.6) 24 (21.4) 25 (22.3)
Spring (Mar, Apr, May) 190 (30.4) 197 (31.5) 26 (23.2) 25 (22.3)
Summer (Jun, Jul, Aug) 125 (20.0) 123 (19.7) 19 (17.0) 19 (17.0)
Autumn (Sep, Oct, Nov) 177 (28.3) 171 (27.3) 43 (38.4) 43 (38.4)
Fasting status, n (%) – –
<3 hrs 253 (40.4) 263 (42.0) 78 (69.6) 80 (71.4)
3–6 hrs 100 (16.0) 97 (15.5) 32 (28.6) 31 (27.7)
>6 hrs 171 (27.3) 165 (26.4) 1 (0.9) 1 (0.9)
Use of pill/HRT/ERT at blood
collection, yes, n (%)
56 (9.0) 56 (9.0) – 6 (5.4) 6 (5.4) –
Characteristics
Height (cm), mean (sd) 167.7 (9.4) 167.2 (9.7) 0.20 166.5 (9.6) 166.3 (8.9) 0.87
Weight (kg), mean (sd) 74.7 (13.6) 73.4 (13.9) 0.06 75.1 (13.6) 74.3 (12.6) 0.55
BMI (kg/m2), mean (sd) 26.6 (4.2) 26.2 (4.1) 0.13 27.0 (3.9) 26.8 (3.8) 0.61
Waist circumference (cm), mean (sd) 89.8 (12.8) 88.3 (12.9) 0.02 90.4 (11.5) 89.3 (10.8) 0.38
Hip circumference (cm), mean (sd) 101.8 (8.6) 101.1 (8.3) 0.2 103.5 (8.8) 102.6 (6.9) 0.33
Waist–hip ratio, mean (sd) 0.9 (0.1) 0.9 (0.1) 0.01 0.9 (0.08) 0.9 (0.09) 0.79
Education level, n (%) 0.20 0.45
Primary school or less 278 (44.4) 248 (39.6) 53 (47.3) 57 (50.9)
Secondary school lower level 142 (22.7) 166 (26.5) 33 (29.5) 28 (25.0)
Secondary school higher level 73 (11.7) 79 (12.6) 1 (0.9) 5 (4.5)
College/University degree 113 (18.1) 116 (18.5) 6 (5.4) 13 (11.6)
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Table 1. Description of PC cases and matched controls for the EPIC and HUNT2 studies separately (Continued)
EPIC HUNT2
Cases
(n5626)
Matched controls
(n5626) p value1
Cases
(n5112)
Matched controls
(n5112) p value1
Smoking status, n (%) <0.01 0.08
Never 233 (37.2) 287 (45.9) 40 (35.7) 48 (42.9)
Past 183 (29.2) 201 (32.1) 36 (32.1) 43 (38.4)
Current 201 (32.1) 133 (21.3) 26 (32.1) 21 (18.8)
Age start smoking (years), mean (sd) 20.1 (6.5) 20.3 (6.4) 0.43 22.8 (8.5) 21.0 (8.1) 0.79
Duration of smoking (years), mean (sd) 29.4 (12.0) 27.4 (12.9) 0.19 32.5 (14.7) 29.6 (14.8) 0.09
Time since quitting (years), mean (sd) 16.0 (11.5) 16.0 (10.3) 0.16 18.1 (11.6) 21.8 (13.2) 0.74
Smoking dose (cig/day), mean (sd) 15.7 (8.4) 16.3 (8.8) 0.35 10.9 (6.4) 10.2 (6.2) 0.16
Smoking habits combined, n (%) <0.01 0.15
Never 233 (37.2) 287 (45.9) 40 (35.7) 48 (42.9)
Former, time since quitting >15 yrs 87 (13.9) 89 (14.2) 18 (16.1) 27 (24.1)
Former, time since quitting 0–15 yrs 90 (14.4) 103 (16.5) 15 (13.4) 14 (12.5)
Current, 0–15 cig/day 97 (15.5) 60 (9.6) 27 (24.1) 17 (15.2)
Current, >15 cig/day 80 (12.8) 52 (8.3) 7 (6.3) 1 (0.9)
Former/current, quitting/dose unknown 30 (4.8) 30 (4.8) 5 (4.5) 5 (4.5)
Physical activity, n (%) 0.53 0.59
Inactive 174 (27.8) 184 (29.4) 12 (10.7) 12 (10.7)
Active 432 (69.0) 426 (68.1) 73 (65.2) 80 (71.4)
Diabetes, yes, n (%) 45 (7.2) 28 (4.5) 0.03 4 (3.6) 7 (6.3) 0.37
Vitamin D status
Serum 25(OH)D (nmol/L), mean (sd) 60.0 (27.3) 59.4 (27.1) 0.57 70.7 (23.8) 64.7 (20.3) 0.05
Quintiles of serum 25(OH)D 0.35 0.18
Q1, n (%) 118 (18.9) 139 (22.2) 9 (8.0) 9 (8.0)
Q2, n (%) 144 (23.0) 126 (20.1) 13 (11.6) 21 (18.8)
Q3, n (%) 131 (21.0) 121 (19.3) 26 (23.2) 26 (23.2)
Q4, n (%) 105 (16.8) 118 (18.9) 23 (20.5) 31 (27.7)
Q5, n (%) 128 (20.5) 122 (19.5) 41 (36.6) 25 (22.3)
Predefined cut-points of serum 25(OH)D 0.90 0.26
25 nmol/L, n(%) 33 (5.3) 39 (6.2) 1 (0.9) 4 (3.6)
>25 to 50 nmol/L, n (%) 214 (34.2) 216 (34.5) 20 (17.9) 21 (18.8)
>50 to 75 nmol/L, n (%) 233 (37.2) 232 (37.1) 46 (41.1) 56 (50.0)
>75 to 100 nmol/L, n (%) 92 (14.7) 90 (14.4) 33 (29.5) 25 (22.3)
> 100 nmol/L, n (%) 54 (8.6) 49 (7.8) 12 (10.7) 6 (5.4)
Dietary variables
Alcohol (g/day)2 6.0 (0.9–19.3) 5.7 (1.1–17.9) 0.64 1.4 (0.0–4.3) 0.7 (0.0–2.9) 0.13
Any vitamin use, n (%) 0.36 0.22
Yes 211 (33.7) 222 (35.5) 12 (10.7) 11 (9.8)
No 337 (53.8) 323 (51.6) 11 (9.8) 17 (15.2)
1p Values for differences in means between cases and controls were determined by paired t test, whereas differences in categorical variables were
determined by conditional logistic regression. No p values were determined for years of follow-up, age at recruitment, sex, residential region, coun-
try, season of blood collection, fasting status, and use of pill/HRT/ERT at blood collection, because these variables were used for matching.
2Median (p25–p75).
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multivariable model, which was developed by individually
adding variables to the model. Variables examined as poten-
tial confounders were body mass index (BMI; weight (kg)/
height(m)2), waist-to-hip ratio, waist circumference (cm), hip
circumference (cm), alcohol consumption (g/d), physical
activity (inactive, active), smoking habits (never smokers, for-
mer smokers who quitted 15 years earlier, former smokers
who quitted between 0 and 15 years earlier, currents smokers
who smoke <15 cigarettes/day, current smokers who smoke
15 cigarettes/day, former/current smokers with years since
quitting/dose unknown), smoking duration, educational level
(primary school or less, secondary school lower level, second-
ary school higher level, college/university degree), diabetes
(yes, no), any vitamin use (yes, no) and season of blood col-
lection (winter: December–February; spring: March–May;
summer: June–August; autumn: September–November). The
final multivariable model included BMI and smoking habits
as these were associated with both the disease and the risk
factor and changed the risk estimate by 10% or more. The
dietary variables red meat, processed meat and fruit and veg-
etable intake were also investigated as potential confounders
for cases and controls from the EPIC study, but they did not
change the point estimates appreciably and were therefore
not included in any model.
To evaluate whether preclinical disease may have influ-
enced the results, additional analyses were conducted after
exclusion of cases that were diagnosed within 2 years after
recruitment and their matched controls (leaving approxi-
mately 87% of the population). In addition, the association
between vitamin D and PC was examined by tertiles of
follow-up time. Further sensitivity analyses were performed
in which only microscopically confirmed PC cases (67%) and
their matched controls were included.
Possible heterogeneity of effects by log2 transformed val-
ues of vitamin D levels between categories of matching fac-
tors (age groups [median split], sex, season of blood
collection, region [North: Norway, Sweden, Denmark, The
Netherlands, Germany and United Kingdom; South: France,
Italy, Spain and Greece], latitude [30–50 and 50–708N] and
country) was tested using the heterogeneity statistic derived
from the inverse variance method.
Joint effects of several factors (in median split or pre-
defined categories) with season-standardized vitamin D con-
centrations (in quartiles) were calculated, for which a com-
bined reference category of the lowest category of these
factors with a low vitamin D concentration was used. These
factors are BMI, physical activity, smoking status, alcohol
consumption, multivitamin use, diabetes at baseline, calcium
intake (only available for the EPIC cohort) and retinol intake
(only available for the EPIC cohort). Interaction (on the mul-
tiplicative scale) was tested by including a product term of
the above-mentioned factors with season-standardized vita-
min D status into the model. In addition, heterogeneity of
effects by log2 transformed values of vitamin D levels by
strata of the above-mentioned factors were tested using the
heterogeneity statistic derived from the inverse variance
method.
All analyses were performed using SAS Software (version
9.3, SAS Institute Inc, Cary, NC, USA). For all analyses two-
sided p< 0.05 were considered statistically significant.
Results
In the EPIC cohort, the mean age of PC cases was 57.7 years
at recruitment and they were followed for 7.0 years on aver-
age (Table 1). PC cases from EPIC were heavier, had a larger
waist circumference and waist–hip ratio, were more likely to
be current smokers and to have diabetes than controls.
In the HUNT2 cohort, the mean age of PC cases was 68.0
years at recruitment and they were followed for 5.8 years on
average. PC cases from HUNT2 were more likely to be cur-
rent smokers and tended to have a longer duration of smok-
ing than controls.
When pre-defined cut-points of vitamin D concentrations
were investigated in relation to PC risk, a trend was observed,
which was not statistically significant (p for trend5 0.09; Table
2). Compared with the reference (> 50 to 75 nmol/L), lower
vitamin D levels showed decreased effect estimates (25.0
Figure 1. Country-specific incidence rate ratios (95% CI) of PC
according to a doubling of standardized circulating 25-hydroxy vita-
min D concentrations. Conditioned on matching factors and
adjusted for BMI and smoking habits. No incidence rate ratios
were obtained for EPIC-Norway due to the small population. p
value for heterogeneity between EPIC-countries was 0.97 and
between the EPIC and HUNT2 cohorts was 0.12.
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nmol/L: IRR (95% CI)5 0.71 (0.42–1.20); >25 to 50 nmol/L:
0.94 (0.72–1.22)), whereas higher levels showed increased effect
estimates (>75 to 100 nmol/L5 1.12 (0.82–1.53); >100 nmol/
L5 1.26 (0.79–2.01)) in the adjusted model.
Season-standardized circulating vitamin D concentrations
were not associated with risk of PC (Table 2). Compared with
the lowest overall quintile (Q1), IRRs with 95% CIs were 1.32
(0.95–1.85) for Q2, 1.14 (0.81–1.62) for Q3, 1.18 (0.83–1.69)
for Q4 and 1.38 (0.94–2.01) for Q5 (p for trend5 0.23). Effect
estimates for cohort-specific quintiles were comparable. A dou-
bling of vitamin D concentrations was also not associated with
PC risk (IRR (95% CI)5 1.16 (0.95–1.41). A model that, in
addition to BMI and smoking habits, was further adjusted for
waist–hip ratio, physical activity, alcohol, diabetes, education
and vitamin use showed similar effect estimates (e.g., IRRlog2
(95% CI)5 1.20 (0.94–1.54)).
When the first 2 years of follow-up were excluded (leaving
approximately 87% of the population in the analyses), the
trend over pre-defined cut-points reached statistical signifi-
cance (p for trend 0.04), whereas the trend over season-
standardized quintiles of vitamin D concentrations did not (p
for trend 0.08). When follow-up time was divided in tertiles,
the trend over pre-defined cut-points as well as the one over
season-standardized quintiles was only statistically significant
in the second tertile (p for trend for increasing tertiles of
follow-up time5 0.48, 0.004 and 0.43 for pre-defined cut-
points and 0.79, 0.004 and 0.51 for quintiles).
The trends over pre-defined cut-points and season-
standardized quintiles were not statistically significant when
only confirmed PC cases (67%) were included in the analyses
(p for trend 0.22 and 0.72, respectively).
No heterogeneity was observed by age (IRRlog2 (95%
CI)5 1.06 (0.79–1.42) for younger age and 1.29 (0.97–1.72)
for older age; pheterogeneity5 0.34), sex (IRRlog2 (95%
CI)5 1.13 (0.83–1.55) for men and 1.18 (0.90–1.53) for
women; pheterogeneity5 0.86), season of blood collection (IRRlog2
(95% CI)5 0.87 (0.48–1.55) for winter, 0.90 (0.51–1.59) for
spring, 0.94 (0.51–1.74) for summer and 1.16 (0.78–1.73) for
autumn; pheterogeneity5 0.82), region (IRRlog2 (95% CI)5 1.18
(0.94–1.48) for north and 1.14 (0.73–1.76) for south
pheterogeneity5 0.88), nor latitude (IRRlog2 (95% CI)5 1.07
(0.71–1.61) for 30–508 N and 1.20 (0.95–1.51) for 50–708 N;
pheterogeneity5 0.63).
Although none of the countries within the EPIC cohort
separately showed a statistically significantly increased PC
risk for every doubling of season-standardized vitamin D
concentrations, all countries except Germany and Greece
showed effect estimates above the null value (p for heteroge-
neity between EPIC countries5 0.97; Fig. 1). The IRR (95%
CI) for every doubling in season-standardized vitamin D con-
centrations was 1.08 (0.87–1.35) for the EPIC cohort, whereas
it was 1.73 (1.00–3.01) for the HUNT2 cohort (p for hetero-
geneity between EPIC and HUNT25 0.12; Fig. 1).
Neither interaction nor heterogeneity of effects was
observed for vitamin D and any of the factors tested (Table 3).
Discussion
In our study, the largest combination of European studies to
date on this topic, higher vitamin D concentrations are not
inversely associated with PC risk. In fact, increasing effect
estimates of PC risk with a borderline statistically significant
trend were observed with increasing pre-defined cut-points of
vitamin D status, whereas season-standardized quintiles did
not show an association with risk of PC.
Our findings are fairly consistent with observations from
other studies as hardly any of them showed evidence of an
inverse association. Although optimal levels of 25(OH)D
have not been definitively determined, a classification of clini-
cally relevant cut-points has been used before. The VDPP25
first used these cut-points, where a low vitamin D concentra-
tion (< 50 nmol/L) compared with a reference category of 50
to <75 nmol was not associated with PC risk, while a high
vitamin D concentration ( 100 nmol/L) was associated with
a statistically significant twofold increase in PC risk (OR
(95% CI)5 2.12 (1.23–3.64)).25 The pooling project included
participants from eight cohorts, among which were the
ATBC study22 and the PLCO cohort.23 Both these studies
already published results on vitamin D status and PC risk,
but divided vitamin D in quintiles instead of clinically
defined cut-points. Using these quintiles, the ATBC study
revealed a nearly threefold increase in PC risk for the highest
quintile in comparison with the lowest quintile (OR (95%
CI)5 2.92 (1.56–5.48; p for trend 0.001).22 In the PLCO, no
association was observed in the overall analysis, but a nearly
fourfold increase in PC risk for the highest versus the lowest
quintile ((OR (95% CI)5 3.91 (1.19–12.85; p for trend 0.10))
was shown in a subgroup of participants living at northern
latitudes.23 In a subsequent analysis, using clinically defined
cut-points, an increase in PC risk was observed for a high
vitamin D concentration ( 100 nmol/L) compared with a
reference category of 50 to <75 nmol ((OR (95% CI)5 3.23
(1.24–8.44)) in the overall group of the PLCO study.24 The
only study that did observe an inverse association between
vitamin D concentrations and PC risk is a pooled analysis of
participants from five cohorts.26 Here, the odds ratio for the
highest quintile of vitamin D concentrations compared with
the lowest quintile was 0.67 (95% CI 0.46–0.97; p for trend
0.03). The inverse linear association observed for quintiles
was not observed when Wolpin et al. divided vitamin D con-
centrations according to clinically relevant cut-points as
defined in the VDPP study.26 However, they also did not
observe an increased PC risk for high vitamin D concentra-
tions of 100 nmol/L. Although we did not detect a direct
association between high vitamin D concentrations and PC
either, effect estimates seemed to increase with increasing
concentrations of vitamin D. In light of these results, we can-
not state that higher vitamin D concentrations are related to
a higher PC risk, but it seems reasonable to conclude that
higher vitamin D concentrations are not related to a lower
PC risk in this population.
Except for the ATBC study from Finland,22 this is the first
study on vitamin D concentrations in relation to PC risk
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among European populations. One may hypothesize that this
relation may differ with the associations observed in popula-
tions from the US, due to differences in latitude and fortified
foods. Most of Europe lies above 378 N latitude, whereas this
is only true for the northern half of the US. Since UVB is
efficiently absorbed by the ozone layer from November
through February above 378 N latitude,39,40 nearly all Euro-
pean residents have low, if any, endogenous vitamin D pro-
duction during these months and are thus more dependent
on vitamin D intake from foods and supplements than resi-
dents from the US. In addition, vitamin D fortification of
foods differs between Europe and the US, where fortification
of milk, for example, is the exception in Europe rather than
the rule in the US.41 As the amount of vitamin D that was
added to milk was not very consistent in the 1990s,42,43 it is
less likely that hypothesized differences in associations
between populations from the US and Europe are due to dif-
ferences in food fortification than to differences in latitude.
Even though there may be a difference in the sources of vita-
min D concentrations between populations from Europe and
the US, the vitamin D concentrations from our European
study are comparable to those from US studies in the 1990s,
and no large differences were observed for the association
between vitamin D concentrations and PC risk.
Although several in vitro and in vivo studies have shown
that vitamin D has anti-carcinogenic properties in general,5,6
few studies have investigated this specifically with respect to
PC. Whether vitamin D has anti-carcinogenic effects on the
pancreas is thus largely unclear. The molecular basis by
which vitamin D may be involved in pancreatic carcinogene-
sis should be further investigated. We propose that certain
genetic variants affecting vitamin D concentrations may
modulate the association between vitamin D and PC risk.
Within the vitamin D pathway, genetic variants in the vita-
min D binding protein (DBP, corresponding gene GC) are
most frequently investigated. It is possible that variants in the
DBP gene may affect the vitamin D binding protein concen-
tration in the circulation and therefore may influence the
vitamin D bioavailability, the role of which is unknown in
pancreatic carcinogenesis. In a recent study of 713 PC cases
and 818 controls from five cohorts within the VDPP, the
association between vitamin D concentrations and PC risk
was not modified by single nucleotide polymorphisms in the
DBP gene or 10 other genes in the vitamin D metabolic
pathway.44 Nevertheless, it should be kept in mind that in
various Genome-Wide Association Studies on vitamin D con-
centrations, genetic variants in GC are among the significant
findings.45,46 To unravel the molecular mechanisms by which
vitamin D may influence pancreatic carcinogenesis, more
studies should investigate vitamin D-gene interactions with
genetic variants in the vitamin D metabolic pathway, but also
including the vitamin D receptor (VDR) and its vitamin D-
mediated transcriptionally regulated (VDRE containing)
genes and their signalling pathways.47
An important strength of our study is the prospective
design with pre-diagnostic measurements of vitamin D
concentrations, which reduces the influence of reversed cau-
sation. In addition, pooling two large European studies
resulted in a relatively large study population. This popula-
tion originates from countries from the north to the south of
Europe, spanning a wide range of sun exposure, many differ-
ent lifestyle patterns, dietary habits and PC incidence. A dif-
ference in vitamin D status was also observed between the
two European studies, where higher concentrations of vita-
min D were observed in the HUNT cohort from the North
of Norway than in the more centrally located EPIC study.
Although this is contrary to what would be expected based
on latitude, this may be due to differences in study popula-
tion, blood sample handling procedures or to a higher use of
cod liver oil supplements, which is a long dietary tradition in
Norway.48 Finally, another strength of our study is that all
samples were transported to the same laboratory for mea-
surement using a single LC-MS/MS method, which shows
close agreement to a reference measurement procedure for
25(OH)D3 and 25(OH)D2 analysis in human serum.
31
A limitation of our study is that only a single baseline
measurement of vitamin D was used. Vitamin D levels dis-
play seasonal variability and a single measurement of vitamin
D may not reflect long-term vitamin D status. However, the
concentration of 25(OH)D in samples collected up to 14
years apart was observed to be sufficiently reliable to be used
in cohort studies.49 Furthermore, we standardized the vitamin
D concentrations by week of blood collection to take season
of blood draw into account. While we could not take some
risk factors of PC risk, such as family history and chronic
pancreatitis, into account due to a lack of information, we
did test other established PC risk factors and included BMI
and smoking habits into the model to adjust for potential
confounding. Although residual confounding by smoking
cannot be ruled out, it is not likely, because the findings
observed in never smokers were similar to the overall result.
In conclusion, among participants from the largest combi-
nation of European studies to date, higher vitamin D concen-
trations are not associated with a lower risk of PC. More
research is needed on the molecular mechanisms by which
vitamin D may influence pancreatic carcinogenesis. Until
there is a better biological understanding of this mechanism,
caution is warranted before guidelines to increase vitamin D
concentrations in healthy persons for the prevention of
cancer can be recommended.
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